A novel substrate for arrhythmias in Chagas disease

Artur Santos-Miranda1, Julliane V Joviano-Santos1, Jaqueline O Sarmento1

  • 1Department of Biophysics, Universidade Federal de São Paulo, São Paulo, Brazil.

Insights

The Na+/Ca2+ exchanger (NCX) contributes to heart rhythm problems in chronic Chagas disease. Blocking NCX may offer a new treatment strategy for arrhythmias in Chagas disease patients.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Molecular Cardiology

Background:

  • Chagas disease (CD) is a neglected tropical disease affecting millions.
  • Chronic CD often leads to heart failure and life-threatening arrhythmias.
  • The cellular mechanisms underlying CD-induced arrhythmias remain incompletely understood.

Purpose of the Study:

  • To investigate the role of the Na+/Ca2+ exchanger (NCX) in electrical remodeling of cardiomyocytes during chronic experimental Chagas disease.
  • To assess the potential of targeting NCX as a therapeutic strategy for Chagas disease-related arrhythmias.

Main Methods:

  • Experimental Chagas disease was induced in C57BL/6 mice using the Colombian strain of Trypanosoma cruzi.
  • Isolated cardiomyocytes from chronically infected mice (180-200 days post-infection) were studied using whole-cell patch-clamp.
  • Cellular excitability and action potential (AP) properties were measured.
  • Real-time PCR was used for parasite detection.

Main Results:

  • Cardiomyocytes from infected mice exhibited prolonged AP repolarization and increased after-depolarizations.
  • Pause-induced spontaneous activity and diastolic transient inward currents were enhanced in chagasic cardiomyocytes.
  • These abnormalities were significantly reduced by blocking NCX with Ni2+ or SEA0400.

Conclusions:

  • This study identifies the Na+/Ca2+ exchanger (NCX) as a key cellular arrhythmogenic substrate in cardiomyocytes from a murine model of chronic Chagas disease.
  • NCX activity contributes to electrical remodeling and arrhythmogenesis in the chronic phase of experimental CD.
  • Targeting NCX represents a potential novel therapeutic approach for managing arrhythmias in Chagas disease.
Abstract

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.1K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.5K
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
1.4K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.1K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.2K
Dysrhythmias II: Classification of Tachyarrhythmias01:28

Dysrhythmias II: Classification of Tachyarrhythmias

Tachyarrhythmias are a type of dysrhythmia where the heart rate exceeds 100 beats per minute. Here are some common types of tachyarrhythmias:Sinus TachycardiaSinus tachycardia originates from increased impulses from the sinus node, leading to an elevated heart rate. It is often triggered by stress, fever, or exercise.Patients may experience palpitations, a sensation of a racing heart, dizziness, and chest discomfort.Causes and Risk Factors: Common causes include physical exertion, emotional...
273